Last reviewed · How we verify
Hydromorphone Hydrochloride Extended-Release Tablets
Hydromorphone hydrochloride is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and pain relief.
Hydromorphone hydrochloride is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and pain relief. Used for Chronic moderate to severe pain requiring around-the-clock opioid therapy.
At a glance
| Generic name | Hydromorphone Hydrochloride Extended-Release Tablets |
|---|---|
| Also known as | Exalgo, Jurnista |
| Sponsor | Qinghai Red Cross Hospital |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Hydromorphone is a potent mu-opioid receptor agonist that crosses the blood-brain barrier and acts on opioid receptors in the brain and spinal cord to modulate pain perception and transmission. The extended-release formulation provides sustained drug delivery over an extended period, allowing for less frequent dosing in chronic pain management. It is approximately 6-7 times more potent than morphine on a milligram-for-milligram basis.
Approved indications
- Chronic moderate to severe pain requiring around-the-clock opioid therapy
Common side effects
- Constipation
- Nausea
- Dizziness
- Somnolence
- Vomiting
- Headache
- Respiratory depression
Key clinical trials
- Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain (EARLY_PHASE1)
- Opioid Use Post-Discharge After Ambulatory Distal Arm Surgery (NA)
- Oral Abuse Potential Study of Nalbuphine (PHASE1)
- Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)
- Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients (PHASE3)
- Dosing Intervals of Opioid Medication for Chronic Pain (PHASE4)
- Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: